We hypothesize that in a large proportion of patients with low-renin hypertension, the underlying pathophysiology involves MR activation and therefore targeted treatment with an MRA will offer greater antihypertensive effects and end-organ protection. Here, NR3C2 is linked to hypertensive disorder.